View Future GrowthZeroStack 과거 순이익 실적과거 기준 점검 0/6ZeroStack 의 수입은 연평균 -11.5%의 비율로 감소해 온 반면, Personal Products 산업은 연평균 10.3%의 비율로 증가했습니다. 매출은 연평균 32.9%의 비율로 증가해 왔습니다.핵심 정보-11.54%순이익 성장률35.24%주당순이익(EPS) 성장률Personal Products 산업 성장률8.70%매출 성장률32.90%자기자본이익률-163.58%순이익률-323.49%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Nov 16Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.11 profit in 3Q 2023)Third quarter 2024 results: US$0.28 loss per share (down from US$0.11 profit in 3Q 2023). Revenue: US$12.5m (down 28% from 3Q 2023). Net loss: US$3.77m (down US$4.52m from profit in 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.Reported Earnings • Aug 13Second quarter 2024 earnings released: US$0.21 loss per share (vs US$5.46 loss in 2Q 2023)Second quarter 2024 results: US$0.21 loss per share (improved from US$5.46 loss in 2Q 2023). Revenue: US$15.7m (down 27% from 2Q 2023). Net loss: US$2.63m (loss narrowed 93% from 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.2% growth forecast for the Personal Products industry in Europe.모든 업데이트 보기Recent updates공시 • May 11ZeroStack Corp., Annual General Meeting, Jul 13, 2026ZeroStack Corp., Annual General Meeting, Jul 13, 2026. Location: dorsey & whitney llp, 66 wellington street west, suite 3400, on m5k 1e6., toronto, Canada공시 • Jan 28+ 2 more updatesFlora Growth Corp. has withdrawn its Follow-on Equity Offering.Flora Growth Corp. has withdrawn its Follow-on Equity Offering. Security Name: Common Shares Security Type: Common Stock공시 • Jan 08Flora Growth Corp. Announces Board and Committee ChangesFlora Growth Corp. unanimously approved by written consent the appointment of (i) Mr. Larry Zeifman as a director of the Company, as a member of the audit committee of the Board (the "Audit Committee"), as a member of the compensation committee of the Board (the "Compensation Committee"), as a member of the nominating and corporate governance committee of the Board (the "Nominating Committee") and as Chair of the Audit Committee and (ii) Mr. Manfred Leventhal as Chair of the Nominating Committee. The Board has determined that Mr. Zeifman is an independent director, meets the applicable standards for Audit Committee service under both the Nasdaq Stock Market Rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and meets the applicable standards for Compensation Committee service under the Nasdaq Stock Market Rules. Mr. Zeifman's appointment fills the vacancy on the Board, the Compensation Committee and the Nominating Committee which resulted from the passing of Harold Wolkin on August 25, 2025.공시 • Sep 23Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $2.12 million.Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $2.12 million. Security Name: Common Shares Security Type: Common Stock Transaction Features: At the Market Offering공시 • May 03Flora Growth Corp. announced that it expects to receive $1.157928 million in fundingFlora Growth Corp. announced that it has entered into a securities purchase agreement with certain investors in connection with the issuance and sale by the Company to the Investors via a private placement of an aggregate of 3,133,011 common shares of the Company, no par value per share at a purchase price of $0.30 per share and 726,992 pre-funded warrants of the Company at a purchase price of$0.2999 per warrant each to purchase one Common Share which shall be immediately exercisable and expire when exercised in full, at an exercise price of $0.0001 per share for the aggregate gross proceeds of up to $ on May 2, 2025. The Company will reimburse the Investors a non-accountable amount of $15,000 for all costs and expenses of outside counsel and disbursements of Bevilacqua PLLC, counsel to one of the Investors, which shall be withheld by such Investor from its purchase price at the closing date of the Private Placement. The net proceeds from the sale of the Common Shares and Pre-funded Warrants were approximately $1,100,000 after deducting estimated expenses relating to the Private Placement. The Securities Purchase Agreement includes customary representations, warranties and covenants by the Company and the Investors. Additionally, the Company has agreed to provide the Investors with customary indemnification under the Securities Purchase Agreement against certain liabilities, including liabilities under the Securities Act of 1933, as amended.공시 • Apr 17Flora Growth Corp., Annual General Meeting, Jul 21, 2025Flora Growth Corp., Annual General Meeting, Jul 21, 2025. Location: dorsey & whitney llp, 66 wellington street west, suite 3400, on m5k 1e6., toronto Canada공시 • Mar 01Flora Growth Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn February 25, 2025, Flora Growth Corp. received a notice from the Listing Qualifications Department of the Nasdaq Stock Market stating that for 30 consecutive business days the Company's common shares did not maintain a minimum closing bid price of $1.00 per share as required for continued listing under Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Common Shares. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until August 25, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Common Shares must be at least $1.00 per share for a minimum of ten consecutive business days before August 25, 2025, at which time the Staff will provide written notification to the Company that it complies with the Minimum Bid Requirement, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Common Shares does not achieve compliance by August 25, 2025, the Company may be eligible for an additional 180-day period to regain compliance, provided that it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, for example, by effecting a reverse stock split, if necessary. The Company intends to actively monitor the closing bid price of the Common Shares and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the Nasdaq Listing Rules.공시 • Feb 12Flora Growth Corp. Appoints Patrick Moloney as Head of Product Development for Its Accessory Brand, VesselFlora Growth Corp. announced the appointment of Patrick Moloney as Head of Product Development for its accessory brand, Vessel. Mr. Moloney brings over two decades of product innovation and leadership experience, having held senior roles in product development at several globally recognized companies. His expertise in design and strategy will help drive Vessel's continued growth in the premium accessories market. Mr. Moloney's career highlights include serving as Design Manager on New Product Innovation at Dyson, where he was responsible for leading a team in developing consumer products. His experience in the highly competitive consumer goods sector was further honed during his tenure as Senior Manager of New Sciences at British American Tobacco, where he was tasked with creating next-generation product offerings. Most recently, as Chief Product Officer at InLab Ventures, Mr. Moloney led the development of innovative products and services across multiple industries, focusing on sustainability and user experience.Mr. Moloney is an inventor of over 300 patents who has brought to market iconic inventions, including the Dyson Supersonic Hairdryer and Dyson Airblade Tap, as well as developing foundational concepts for Dyson's floorcare range. At British American Tobacco, Mr. Moloney's contributions resulted in over 170 inventions and 120 patent filings, representing about 25% of British American Tobacco's total filings during his tenure.in his new role, Mr. Moloney will oversee Vessel's product development, leveraging his extensive experience to drive innovation, enhance product quality, and strengthen Vessel's market position. As the cannabis accessories market evolves, his appointment underscores Flora's commitment to providing consumers with the highest-quality products and elevating the Vessel brand.공시 • Feb 06Flora Growth Corp. (NasdaqCM:FLGC) acquired United Beverage Distribution Inc from a group of shareholders for $3.7 million.Flora Growth Corp. (NasdaqCM:FLGC) entered into a share purchase agreement to acquire United Beverage Distribution Inc from a group of shareholders for $3.7 million on January 30, 2025. The consideration consists of 923,744 common stock of Flora and promissory notes in an aggregate principal amount of $2.8 million to be issued to the sellers. The agreement were unanimously approved by the disinterested directors of Flora. Flora Growth Corp. (NasdaqCM:FLGC) completed the acquisition of United Beverage Distribution Inc from a group of shareholders on February 4, 2025.공시 • Dec 17Flora Growth Corp. has completed a Follow-on Equity Offering in the amount of $3.5625 million.Flora Growth Corp. has completed a Follow-on Equity Offering in the amount of $3.5625 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,850,000 Price\Range: $1.25 Discount Per Security: $0.0875 Transaction Features: Registered Direct Offering공시 • Dec 15Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $3.5625 million.Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $3.5625 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,850,000 Price\Range: $1.25 Transaction Features: Registered Direct Offering공시 • Dec 13Flora Growth Corp. has withdrawn its Follow-on Equity Offering in the amount of $3.794 million.Flora Growth Corp. has withdrawn its Follow-on Equity Offering in the amount of $3.794 million. Security Name: Common Shares Security Type: Common Stock Transaction Features: At the Market OfferingNew Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$18m Forecast net loss in 1 year: US$1.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.6m net loss next year). Market cap is less than US$100m (€14.8m market cap, or US$15.6m).Reported Earnings • Nov 16Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.11 profit in 3Q 2023)Third quarter 2024 results: US$0.28 loss per share (down from US$0.11 profit in 3Q 2023). Revenue: US$12.5m (down 28% from 3Q 2023). Net loss: US$3.77m (down US$4.52m from profit in 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.공시 • Oct 11Flora Growth Corp. Appoints Manfred Ziegler as Managing DirectorFlora Growth Corp. announced the appointment of Dr. Manfred Ziegler as a Managing Director. Dr. Ziegler, a renowned figure in the pharmaceutical industry, brings decades o expertise, notably his leadership as Managing Director of CC Pharma and his pivotal role in the sale of CC Pharma to Tilray, one of the world's leading cannabis companies. With the appointment of Dr. Ziegler, Flora Growth is poised to accelerate its ambition to become one of the leading cannabis companies in Germany. His strategic leadership and proven ability to drive growth in complex markets will be instrumental as Flora expands its operations in Germany, targeting increased market share and a stronger foothold in Europe's rapidly evolving cannabis sector. Dr. Ziegler's tenure at CC Pharma marked a period of growth and strategic innovation. As Managing Director, he transformed the company into one of Europe's leading pharmaceutical distributors, with a robust portfolio and a significance presence in the European market. His leadership was instrument in the successful acquisition of CC Pharma by Tilray. The sale of CC Pharma to Tilray was a significant transaction in the cannabis and pharmaceutical sectors. This acquisition positioned Tilray as a key player in the European medical cannabis market, leveraging CC Pharma's established distribution network to expand its reach in the rapidly growing sector. Dr. Manfred Ziegler is a seasoned executive with over 30 years of experience in the pharmaceutical and healthcare sectors, recognized for his expertise in corporate restructuring and business transformation. Prior to his tenure at CC Pharma, Dr. Ziegler held leadership roles at several prominent companies, where he managed complex international operations and contributed to substantial revenue growth. His track record of strategic realignment and operational efficiency has made him a respected leader in the industry. In his role as Managing Director, Dr. Ziegler will work closely with Flora's executive team, providing insights and guidance on international distribution strategies, regulatory compliance, and market expansion. His understanding of the German market, combined with his experience in overseeing large- scale transactions, will be critical as Flora accelerates its growth plans and pursues opportunities in Europe. One of Dr. Ziegler's key objectives will be to spearhead the launch of the Company's parallel import business in Germany. Parallel importing involves purchasing pharmaceutical products from other EU countries where prices are lower, and then importing them into Germany to sell at competitive rates. This practice is highly regulated but provides an opportunity to reduce costs for consumers and increase Flora's market presence. Dr. Ziegler's vast experience in the pharmaceutical sector, particularly in navigating regulatory complexities and optimizing supply chains, will be critical in establishing Flora as a leader in this space, helping the company provide affordable, high-quality products to the German market.공시 • Sep 12Flora Growth Corp. Announces Board ChangesFlora Growth Corp. announced the appointment of Harold Wolkin as an independent director on its Board of Directors. In this role, Mr. Wolkin will also serve as a member of each of the Company's committees, including as Chair of the Audit Committee. Mr. Wolkin brings over 30 years of progressive experience in the finance sector, having held significant roles in investment banking, including positions at BMO Capital Markets and Dundee Capital Markets. His extensive background and expertise will be instrumental in guiding Flora's financial strategy and governance as the Company continues to expand its global operations. In addition to his new role at Flora, Mr. Wolkin currently serves on the boards of several publicly listed companies. He is the Audit Committee Chair at Baylin Technologies Inc, the Lead Independent Director and Audit Committee Chair at Cipher Pharmaceuticals, Chairman of Femto Technologies Inc. Mr. Wolkin has also made notable contributions to the financial community as a past President of the CFA Society Toronto, and he has been a member of the Chartered Financial Institute since 1980, holding the Chartered Financial Analyst (CFA) designation. Mr. Wolkin holds a Bachelor of Arts in Economics from York University and a Master of Arts in Economics and Finance from the University of Toronto. He is also a graduate and member of the Institute of Corporate Directors, further underscoring his commitment to excellence in corporate governance. Concurrently with Mr. Wolkin's appointment, Flora announced the appointment of Mr. Clifford Starke as Chairman of the Board of Directors. Mr. Starke is currently the Chief Executive Officer of the Company.공시 • Sep 01Flora Growth Announces Update on Compliance with the Audit Committee Composition Requirements of Nasdaq Listing Rule 5605(c)(2)(A)After giving effect to Mr. Kevin Taylor's resignation, the audit committee of the Board of Directors (the ‘Board’) of Flora Growth Corp. (the ‘Company’), no longer had three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A). The Company informed Nasdaq of the foregoing on August 27, 2024. On August 29, 2024, the Company appointed Mr. Harold Wolkin as an independent director and member of each of the Company's audit committee, compensation committee and nominating and corporate governance committee, thereby regaining compliance with Nasdaq Listing Rule 5605(c)(2)(A). After giving effect to Mr. Wolkin's appointment, the audit committee of the Board has three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A). The Company informed Nasdaq of the foregoing on August 30, 2024. As a result of the foregoing, the Company expects Nasdaq to confirm that it has regained compliance with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A).Reported Earnings • Aug 13Second quarter 2024 earnings released: US$0.21 loss per share (vs US$5.46 loss in 2Q 2023)Second quarter 2024 results: US$0.21 loss per share (improved from US$5.46 loss in 2Q 2023). Revenue: US$15.7m (down 27% from 2Q 2023). Net loss: US$2.63m (loss narrowed 93% from 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.2% growth forecast for the Personal Products industry in Europe.Board Change • Jul 22High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Strategic Advisor Juan Galan is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Jun 06Flora Growth Corp. (NasdaqCM:FLGC) acquired Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) for CAD 0.87 million.Flora Growth Corp. (NasdaqCM:FLGC) entered into a Share Purchase Agreement to acquire Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) for CAD 0.87 million on June 4, 2024. The consideration consist of issue of 0.55 million common equity of Flora Growth Corp. having a value of CAD 0.87 million to be issued for common equity of Australian Vaporizers Pty Ltd. As part of the agreement, Flora Growth agreed to acquire 100% of issued and outstanding common shares of Australian Vaporizers. Kronos Capital Partners acted as financial advisor for Lifeist Wellness Inc. Flora Growth Corp. (NasdaqCM:FLGC) completed the acquisition of Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) on June 4, 2024.매출 및 비용 세부 내역ZeroStack가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:7300 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2536-11511030 Sep 2558-1624030 Jun 2555-1524031 Mar 2553-1324031 Dec 2436-911030 Sep 2446-1412030 Jun 2456-1114031 Mar 2475-4822031 Dec 2376-4724030 Sep 2369-5024030 Jun 2361-5728031 Mar 2348-4227031 Dec 2233-4630030 Sep 2228-4833030 Jun 2220-4529031 Mar 2213-2626031 Dec 219-2120030 Sep 214-1515030 Jun 212-1716031 Mar 211-1514031 Dec 200-1412030 Jun 200-440양질의 수익: 7300 은(는) 현재 수익성이 없습니다.이익 마진 증가: 7300는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 7300은 수익성이 없으며 지난 5년 동안 손실이 연평균 11.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 7300의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 7300은 수익성이 없어 지난 해 수익 성장률을 Personal Products 업계(2.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 7300는 현재 수익성이 없으므로 자본 수익률이 음수(-163.58%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHousehold 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/28 20:45종가2026/01/29 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ZeroStack Corp.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rommel DionisioAegis Capital CorporationWilliam KirkRoth Capital Partners
Reported Earnings • Nov 16Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.11 profit in 3Q 2023)Third quarter 2024 results: US$0.28 loss per share (down from US$0.11 profit in 3Q 2023). Revenue: US$12.5m (down 28% from 3Q 2023). Net loss: US$3.77m (down US$4.52m from profit in 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.
Reported Earnings • Aug 13Second quarter 2024 earnings released: US$0.21 loss per share (vs US$5.46 loss in 2Q 2023)Second quarter 2024 results: US$0.21 loss per share (improved from US$5.46 loss in 2Q 2023). Revenue: US$15.7m (down 27% from 2Q 2023). Net loss: US$2.63m (loss narrowed 93% from 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.2% growth forecast for the Personal Products industry in Europe.
공시 • May 11ZeroStack Corp., Annual General Meeting, Jul 13, 2026ZeroStack Corp., Annual General Meeting, Jul 13, 2026. Location: dorsey & whitney llp, 66 wellington street west, suite 3400, on m5k 1e6., toronto, Canada
공시 • Jan 28+ 2 more updatesFlora Growth Corp. has withdrawn its Follow-on Equity Offering.Flora Growth Corp. has withdrawn its Follow-on Equity Offering. Security Name: Common Shares Security Type: Common Stock
공시 • Jan 08Flora Growth Corp. Announces Board and Committee ChangesFlora Growth Corp. unanimously approved by written consent the appointment of (i) Mr. Larry Zeifman as a director of the Company, as a member of the audit committee of the Board (the "Audit Committee"), as a member of the compensation committee of the Board (the "Compensation Committee"), as a member of the nominating and corporate governance committee of the Board (the "Nominating Committee") and as Chair of the Audit Committee and (ii) Mr. Manfred Leventhal as Chair of the Nominating Committee. The Board has determined that Mr. Zeifman is an independent director, meets the applicable standards for Audit Committee service under both the Nasdaq Stock Market Rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and meets the applicable standards for Compensation Committee service under the Nasdaq Stock Market Rules. Mr. Zeifman's appointment fills the vacancy on the Board, the Compensation Committee and the Nominating Committee which resulted from the passing of Harold Wolkin on August 25, 2025.
공시 • Sep 23Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $2.12 million.Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $2.12 million. Security Name: Common Shares Security Type: Common Stock Transaction Features: At the Market Offering
공시 • May 03Flora Growth Corp. announced that it expects to receive $1.157928 million in fundingFlora Growth Corp. announced that it has entered into a securities purchase agreement with certain investors in connection with the issuance and sale by the Company to the Investors via a private placement of an aggregate of 3,133,011 common shares of the Company, no par value per share at a purchase price of $0.30 per share and 726,992 pre-funded warrants of the Company at a purchase price of$0.2999 per warrant each to purchase one Common Share which shall be immediately exercisable and expire when exercised in full, at an exercise price of $0.0001 per share for the aggregate gross proceeds of up to $ on May 2, 2025. The Company will reimburse the Investors a non-accountable amount of $15,000 for all costs and expenses of outside counsel and disbursements of Bevilacqua PLLC, counsel to one of the Investors, which shall be withheld by such Investor from its purchase price at the closing date of the Private Placement. The net proceeds from the sale of the Common Shares and Pre-funded Warrants were approximately $1,100,000 after deducting estimated expenses relating to the Private Placement. The Securities Purchase Agreement includes customary representations, warranties and covenants by the Company and the Investors. Additionally, the Company has agreed to provide the Investors with customary indemnification under the Securities Purchase Agreement against certain liabilities, including liabilities under the Securities Act of 1933, as amended.
공시 • Apr 17Flora Growth Corp., Annual General Meeting, Jul 21, 2025Flora Growth Corp., Annual General Meeting, Jul 21, 2025. Location: dorsey & whitney llp, 66 wellington street west, suite 3400, on m5k 1e6., toronto Canada
공시 • Mar 01Flora Growth Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn February 25, 2025, Flora Growth Corp. received a notice from the Listing Qualifications Department of the Nasdaq Stock Market stating that for 30 consecutive business days the Company's common shares did not maintain a minimum closing bid price of $1.00 per share as required for continued listing under Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Common Shares. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until August 25, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Common Shares must be at least $1.00 per share for a minimum of ten consecutive business days before August 25, 2025, at which time the Staff will provide written notification to the Company that it complies with the Minimum Bid Requirement, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Common Shares does not achieve compliance by August 25, 2025, the Company may be eligible for an additional 180-day period to regain compliance, provided that it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, for example, by effecting a reverse stock split, if necessary. The Company intends to actively monitor the closing bid price of the Common Shares and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the Nasdaq Listing Rules.
공시 • Feb 12Flora Growth Corp. Appoints Patrick Moloney as Head of Product Development for Its Accessory Brand, VesselFlora Growth Corp. announced the appointment of Patrick Moloney as Head of Product Development for its accessory brand, Vessel. Mr. Moloney brings over two decades of product innovation and leadership experience, having held senior roles in product development at several globally recognized companies. His expertise in design and strategy will help drive Vessel's continued growth in the premium accessories market. Mr. Moloney's career highlights include serving as Design Manager on New Product Innovation at Dyson, where he was responsible for leading a team in developing consumer products. His experience in the highly competitive consumer goods sector was further honed during his tenure as Senior Manager of New Sciences at British American Tobacco, where he was tasked with creating next-generation product offerings. Most recently, as Chief Product Officer at InLab Ventures, Mr. Moloney led the development of innovative products and services across multiple industries, focusing on sustainability and user experience.Mr. Moloney is an inventor of over 300 patents who has brought to market iconic inventions, including the Dyson Supersonic Hairdryer and Dyson Airblade Tap, as well as developing foundational concepts for Dyson's floorcare range. At British American Tobacco, Mr. Moloney's contributions resulted in over 170 inventions and 120 patent filings, representing about 25% of British American Tobacco's total filings during his tenure.in his new role, Mr. Moloney will oversee Vessel's product development, leveraging his extensive experience to drive innovation, enhance product quality, and strengthen Vessel's market position. As the cannabis accessories market evolves, his appointment underscores Flora's commitment to providing consumers with the highest-quality products and elevating the Vessel brand.
공시 • Feb 06Flora Growth Corp. (NasdaqCM:FLGC) acquired United Beverage Distribution Inc from a group of shareholders for $3.7 million.Flora Growth Corp. (NasdaqCM:FLGC) entered into a share purchase agreement to acquire United Beverage Distribution Inc from a group of shareholders for $3.7 million on January 30, 2025. The consideration consists of 923,744 common stock of Flora and promissory notes in an aggregate principal amount of $2.8 million to be issued to the sellers. The agreement were unanimously approved by the disinterested directors of Flora. Flora Growth Corp. (NasdaqCM:FLGC) completed the acquisition of United Beverage Distribution Inc from a group of shareholders on February 4, 2025.
공시 • Dec 17Flora Growth Corp. has completed a Follow-on Equity Offering in the amount of $3.5625 million.Flora Growth Corp. has completed a Follow-on Equity Offering in the amount of $3.5625 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,850,000 Price\Range: $1.25 Discount Per Security: $0.0875 Transaction Features: Registered Direct Offering
공시 • Dec 15Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $3.5625 million.Flora Growth Corp. has filed a Follow-on Equity Offering in the amount of $3.5625 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,850,000 Price\Range: $1.25 Transaction Features: Registered Direct Offering
공시 • Dec 13Flora Growth Corp. has withdrawn its Follow-on Equity Offering in the amount of $3.794 million.Flora Growth Corp. has withdrawn its Follow-on Equity Offering in the amount of $3.794 million. Security Name: Common Shares Security Type: Common Stock Transaction Features: At the Market Offering
New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$18m Forecast net loss in 1 year: US$1.6m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.9m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$1.6m net loss next year). Market cap is less than US$100m (€14.8m market cap, or US$15.6m).
Reported Earnings • Nov 16Third quarter 2024 earnings released: US$0.28 loss per share (vs US$0.11 profit in 3Q 2023)Third quarter 2024 results: US$0.28 loss per share (down from US$0.11 profit in 3Q 2023). Revenue: US$12.5m (down 28% from 3Q 2023). Net loss: US$3.77m (down US$4.52m from profit in 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.
공시 • Oct 11Flora Growth Corp. Appoints Manfred Ziegler as Managing DirectorFlora Growth Corp. announced the appointment of Dr. Manfred Ziegler as a Managing Director. Dr. Ziegler, a renowned figure in the pharmaceutical industry, brings decades o expertise, notably his leadership as Managing Director of CC Pharma and his pivotal role in the sale of CC Pharma to Tilray, one of the world's leading cannabis companies. With the appointment of Dr. Ziegler, Flora Growth is poised to accelerate its ambition to become one of the leading cannabis companies in Germany. His strategic leadership and proven ability to drive growth in complex markets will be instrumental as Flora expands its operations in Germany, targeting increased market share and a stronger foothold in Europe's rapidly evolving cannabis sector. Dr. Ziegler's tenure at CC Pharma marked a period of growth and strategic innovation. As Managing Director, he transformed the company into one of Europe's leading pharmaceutical distributors, with a robust portfolio and a significance presence in the European market. His leadership was instrument in the successful acquisition of CC Pharma by Tilray. The sale of CC Pharma to Tilray was a significant transaction in the cannabis and pharmaceutical sectors. This acquisition positioned Tilray as a key player in the European medical cannabis market, leveraging CC Pharma's established distribution network to expand its reach in the rapidly growing sector. Dr. Manfred Ziegler is a seasoned executive with over 30 years of experience in the pharmaceutical and healthcare sectors, recognized for his expertise in corporate restructuring and business transformation. Prior to his tenure at CC Pharma, Dr. Ziegler held leadership roles at several prominent companies, where he managed complex international operations and contributed to substantial revenue growth. His track record of strategic realignment and operational efficiency has made him a respected leader in the industry. In his role as Managing Director, Dr. Ziegler will work closely with Flora's executive team, providing insights and guidance on international distribution strategies, regulatory compliance, and market expansion. His understanding of the German market, combined with his experience in overseeing large- scale transactions, will be critical as Flora accelerates its growth plans and pursues opportunities in Europe. One of Dr. Ziegler's key objectives will be to spearhead the launch of the Company's parallel import business in Germany. Parallel importing involves purchasing pharmaceutical products from other EU countries where prices are lower, and then importing them into Germany to sell at competitive rates. This practice is highly regulated but provides an opportunity to reduce costs for consumers and increase Flora's market presence. Dr. Ziegler's vast experience in the pharmaceutical sector, particularly in navigating regulatory complexities and optimizing supply chains, will be critical in establishing Flora as a leader in this space, helping the company provide affordable, high-quality products to the German market.
공시 • Sep 12Flora Growth Corp. Announces Board ChangesFlora Growth Corp. announced the appointment of Harold Wolkin as an independent director on its Board of Directors. In this role, Mr. Wolkin will also serve as a member of each of the Company's committees, including as Chair of the Audit Committee. Mr. Wolkin brings over 30 years of progressive experience in the finance sector, having held significant roles in investment banking, including positions at BMO Capital Markets and Dundee Capital Markets. His extensive background and expertise will be instrumental in guiding Flora's financial strategy and governance as the Company continues to expand its global operations. In addition to his new role at Flora, Mr. Wolkin currently serves on the boards of several publicly listed companies. He is the Audit Committee Chair at Baylin Technologies Inc, the Lead Independent Director and Audit Committee Chair at Cipher Pharmaceuticals, Chairman of Femto Technologies Inc. Mr. Wolkin has also made notable contributions to the financial community as a past President of the CFA Society Toronto, and he has been a member of the Chartered Financial Institute since 1980, holding the Chartered Financial Analyst (CFA) designation. Mr. Wolkin holds a Bachelor of Arts in Economics from York University and a Master of Arts in Economics and Finance from the University of Toronto. He is also a graduate and member of the Institute of Corporate Directors, further underscoring his commitment to excellence in corporate governance. Concurrently with Mr. Wolkin's appointment, Flora announced the appointment of Mr. Clifford Starke as Chairman of the Board of Directors. Mr. Starke is currently the Chief Executive Officer of the Company.
공시 • Sep 01Flora Growth Announces Update on Compliance with the Audit Committee Composition Requirements of Nasdaq Listing Rule 5605(c)(2)(A)After giving effect to Mr. Kevin Taylor's resignation, the audit committee of the Board of Directors (the ‘Board’) of Flora Growth Corp. (the ‘Company’), no longer had three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A). The Company informed Nasdaq of the foregoing on August 27, 2024. On August 29, 2024, the Company appointed Mr. Harold Wolkin as an independent director and member of each of the Company's audit committee, compensation committee and nominating and corporate governance committee, thereby regaining compliance with Nasdaq Listing Rule 5605(c)(2)(A). After giving effect to Mr. Wolkin's appointment, the audit committee of the Board has three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A). The Company informed Nasdaq of the foregoing on August 30, 2024. As a result of the foregoing, the Company expects Nasdaq to confirm that it has regained compliance with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A).
Reported Earnings • Aug 13Second quarter 2024 earnings released: US$0.21 loss per share (vs US$5.46 loss in 2Q 2023)Second quarter 2024 results: US$0.21 loss per share (improved from US$5.46 loss in 2Q 2023). Revenue: US$15.7m (down 27% from 2Q 2023). Net loss: US$2.63m (loss narrowed 93% from 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.2% growth forecast for the Personal Products industry in Europe.
Board Change • Jul 22High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Strategic Advisor Juan Galan is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Jun 06Flora Growth Corp. (NasdaqCM:FLGC) acquired Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) for CAD 0.87 million.Flora Growth Corp. (NasdaqCM:FLGC) entered into a Share Purchase Agreement to acquire Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) for CAD 0.87 million on June 4, 2024. The consideration consist of issue of 0.55 million common equity of Flora Growth Corp. having a value of CAD 0.87 million to be issued for common equity of Australian Vaporizers Pty Ltd. As part of the agreement, Flora Growth agreed to acquire 100% of issued and outstanding common shares of Australian Vaporizers. Kronos Capital Partners acted as financial advisor for Lifeist Wellness Inc. Flora Growth Corp. (NasdaqCM:FLGC) completed the acquisition of Australian Vaporizers Pty Ltd. from Lifeist Wellness Inc. (TSXV:LFST) on June 4, 2024.